Viviane Monges
Independent Non-Executive DirectorMs. Viviane Monges is Independent Director of bioMérieux S.A. from May 23, 2024. Ms. Monges serves as Director at Ferring Holding SA since July 01, 2023. She was Interim Chief Executive Officer at Euroapi S. A. since October 30, 2023 until March 01, 2024 and served as Chairman of the Board until 2025 and had been its Director since May 04, 2022 until 2025. She has been Independent Non-Executive Director of ADC Therapeutics SA since June 11, 2021. She serves as a Board of Directors at Novo Holdings A/S, BioMerieux and Ferring Pharmaceuticals. She had been Independent Director at DBV Technologies S. A. since May 24, 2019 until October 03, 2022. She serves as Independent Non-Executive Director at Pharvaris N. V. since June 29, 2021. Ms. Monges served as Chief Financial Officer of the Nestlé Business Excellence Division at Nestlé. Ms. Monges is a Senior Global Finance Executive who had a diverse and international career mostly in the Pharmaceutical industry. She has executive-level financial leadership expertise with global corporations, predominantly in the pharmaceutical industry. She is a veteran Chief Financial Officer (CFO) who has worked cross-functionally at both large and small companies deploying innovative strategies and building out finance teams. She started her career in Venezuela with Renault and in Hong Kong with the French News Agency where she was Finance Head for Asia Pacific. She is a Board Member of Union Chimique Belge Biopharmaceutical Company S. A. and Idorsia Pharmaceuticals ltd. Ms. Monges had been a Director at Idorsia Ltd. since April 24, 2018 until May 12, 2021 and Voluntis SA until December 2021. She is furthermore a strategic advisor to NeoMedLight in France. She focused then her career in the Pharmaceutical industry, joining Wyeth Pharmaceuticals in 1997 where she held several leadership roles, including Chief Financial Officer for Europe Region and Chief Financial Officer of the Global Pharma business unit. During that time, she participated in the geographic expansion in Europe as well as the launch of several key products such as Effexor, Enbrel and Tazocin. From 2006 to 2010. Ms. Monges was with Novartis OTC, as Europe Chief Financial Officer, then as Global Division Chief Financial Officer. In 2010, she joined Galderma, a Specialty Multinational Dermatology Company, later acquired by Nestlé. As Group Chief Financial Officer, she contributed to a fast growth several significant major acquisitions. She had been Independent Director of UCB SA since May 03, 2017 until April 27, 2023. She is Member of the Strategic Board of Neomedlight. Ms. Monges also served as CFO of European Pharmaceuticals at Wyeth/Pfizer and as CFO of the Global Pharmaceutical Business unit of Wyeth/Pfizer. Ms. Monges holds MBA degree in Finance from Ecole Supérieure de Commerce de Paris.
Positions
- Company NamePharvaris N.V.Stock CodePHVSPositionIndependent Non-Executive DirectorColleagues
- BABerndt Axel Edvard ModigCo-Founder, CEO & Executive Director
- DPDavid P. MeekerIndependent Non-Executive Chair
- PLPeng LuPresident
- DWDavid W. NassifCFO, Chief Legal Officer & Corporate Secretary
- ANAnna NijdamHead of Strategic Finance & Principal Accounting Officer
- SAStefan AbeleChief Technology Operations Officer
- HJHans J. G. C. P. SchikanIndependent & Non-Executive Vice Chairman
- RGRobert GlassmanIndependent Non-Executive Director
